Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
PMID: 34694878
2022
Antimicrobial agents and chemotherapy
Table: Y318F
HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
PMID: 34762770
2021
Journal of the International AIDS Society
Table: Y318F
HIV-1 Drug Resistance Among Treatment-Naive Transgenders from India.
PMID: 34652967
2021
AIDS research and human retroviruses
Abstract: Mutations M184V, A98G, K103N, G190A, and Y318F associated with resistance to nucleoside reverse transcriptase inhibitor and non-nucleoside reverse transcriptase inhibitors were observed.
Review of Doravirine Resistance Patterns Identified in Participants During Clinical Development.
PMID: 32925358
2020
Journal of acquired immune deficiency syndromes (1999)
Method: Among these, 5 isolates showed RT V106 (V106I, V106V/I, V106A, and V106M/T) substitutions in combination with one or more of A98A/G, H221H/Y, P225P/H, F227 (as F227C or F227C/R), or Y318Y/F RT substitutions, and 1 had genotypic resistance conferred through a Y188L substitution alone.
Method: One isolate displayed the Y318Y/F DOR resistance-associated RT substitution but did not show phenotypic resistance.|mg
Pharmaceutical, clinical, and resistance information on doravirine, a novel non-nucleoside reverse transcriptase inhibitor for the treatment of HIV-1 infection.
Introduction: F227C or Y318F alone may be linked to clinical resistance against DOR.
High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
PMID: 32105319
2020
The Journal of antimicrobial chemotherapy
Table: Y318F
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations.
PMID: 32030406
2020
The Journal of antimicrobial chemotherapy
Abstract: METHODS: We used the WHO 2009 list to investigate the prevalence of NNRTI, NRTI and PI TDR, in treatment-naive HIV-1-infected patients, adding mutations E138A/G/K/Q/R, V106I, V108I, V179L, G190Q, H221Y, F227C/L/V, M230IDR, L234I, P236L and Y318F in RT.
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Result: For NNRTIs, the most prevalent drug resistance mutations were K103 N (1.59%), V179D + K103R (1.33%), Y181C (0.80%), V108I (0.53%), Y188L (0.53%), G190A (0.53%), H221Y (0.53%), Y318F (0.53%), A98G (0.27%), V106A (0.27%), E138A (0.27%), E138R (0.27%), Y188C (0.27%) and M230 L (0.27%).
HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting.
PMID: 31117863
2019
Journal of the International Association of Providers of AIDS Care
HIV mutation literature information.
PMID: 
2022
Antimicrobial agents and chemotherapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT